About Gemini Therapeutics
Gemini Therapeutics is a Healthcare company based in Cambridge (United States) founded in 2015. Developer of precision therapeutics for dry AMD and rare genetic diseases. Gemini Therapeutics has raised $44.5 million across 2 funding rounds from investors including Orbimed, Atlas Venture and Lightstone Ventures. The company has 45 employees. Its chief executive, as recorded, is Georges Gemayel. Gemini Therapeutics offers products and services including Therapeutic Pipeline and Precision Medicine Platform. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include Insitro, BridgeBio and Forge Biologics; 3 of its 3 listed competitors have raised funding.
Company details
Gemini Therapeutics was founded in 2015 and is based in Cambridge, United States. The company operates in the biotechnology sector, focusing on precision therapeutics for dry age-related macular degeneration and rare genetic diseases. A genome-driven and multi-modal approach is employed in drug discovery, with treatments targeted to specific genetic mutations and incorporating various modalities rather than a single method.
- Headquarters Cambridge, United States
- Employees 45
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website geminitherapeutics.com
- Social LinkedIn X
- Legal Name Gemini Therapeutics
- Total Equity Funding$44.5M (USD)
in 2 rounds
- Latest Funding Round$42.5M (USD), Series A
Oct 2017
- InvestorsOrbimed
& 2 more
- Employee Count45
Products & Services of Gemini Therapeutics
Gemini Therapeutics offers a comprehensive portfolio of products and services, including Therapeutic Pipeline and Precision Medicine Platform.
Develops targeted therapies for genetically-defined eye diseases.
Identifies genetic variants for disease treatment development.
Funding Insights of Gemini Therapeutics
Gemini Therapeutics has successfully raised a total of $44.5M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $42.5 million completed in October 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $44.5M
- Total Rounds 2
- Last Round Series A — $42.5M
- First Round $2M
(May 2016)
- Investors Count 3
All 2 funding rounds of Gemini Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2017 | $42.5M | Series A | – | Atlas Venture, Lightstone Ventures | – |
| May 2016 | $2M | Seed | – | – | – |
3 investors in total: 3 institutional.
Investors in Gemini Therapeutics
Gemini Therapeutics has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Orbimed, Atlas Venture and Lightstone Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Venture capital fund and fund of funds focused on the life science sector | lightstonevc.com | Menlo Park, United States | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States |
Investor details for Gemini Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Gemini Therapeutics
14 people are tracked at Gemini Therapeutics (8 in leadership, 6 in board & advisors); the tracked headcount is 45.
| Name | Role | Group |
|---|---|---|
Georges Gemayel | CEO & President | Leadership |
Jason Meyenburg | CEO & President | Leadership |
Walter Strapps | Chief Scientific Officer | Leadership |
Brian Piekos | Chief Financial Officer | Leadership |
Suresh Katti | VP, Research | Leadership |
Scott Lauder | CTO | Leadership |
Samuel Barone | Chief Medical Officer | Leadership |
Precillia Redmond | Chief People Officer | Leadership |
Carl L. Gordon | Director | Board & advisors |
Jean George | Director | Board & advisors |
Tuyen Ong | Independent Board Member | Board & advisors |
Jason Rhodes | Director | Board & advisors |
Steve Squinto | Chairman of the Board | Board & advisors |
David Lubner | Independent Director | Board & advisors |
Complete people profiles for Gemini Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Gemini Therapeutics
3 dated milestones of Gemini Therapeutics across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Gemini Therapeutics is founded.
- Funding First funding round of $2.0M.
- Funding Latest funding round, Series A, of $42.5M.
Competitors of Gemini Therapeutics
Gemini Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Insitro, BridgeBio and Forge Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. |
Detailed competitors of Gemini Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Gemini Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Gemini Therapeutics
Complete news archive for Gemini Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gemini Therapeutics
Gemini Therapeutics was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Gemini Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Georges Gemayel is the CEO of Gemini Therapeutics, as recorded in our data.
Gemini Therapeutics is a funded company, having raised a total of $44.5M across 2 funding rounds to date. The company's 1st funding round was a Seed of $2M, raised on May 2016.
Gemini Therapeutics has 45 employees.
Gemini Therapeutics was founded in 2015 and is based in Cambridge, United States. The company operates in the biotechnology sector, focusing on precision therapeutics for dry age-related macular degeneration and rare genetic diseases. A genome-driven and multi-modal approach is employed in drug discovery, with treatments targeted to specific genetic mutations and incorporating various modalities rather than a single method.
Gemini Therapeutics's top competitors include BridgeBio, Forge Biologics and Insitro.
Gemini Therapeutics offers Therapeutic Pipeline and Precision Medicine Platform.
Gemini Therapeutics has 3 investors. Key investors include Orbimed, Atlas Venture, and Lightstone Ventures.
Gemini Therapeutics operates through Gemini Therapeutics.